EMJ Oncology 9 [Supplement 1] . 2021

In this issue

FOUR leading experts in the field of oncology were brought together in an interview to discuss the epidemiology, treatment decisions, and emerging treatment paradigms of EGFR-mutated advanced non-small cell lung cancer (NSCLC). Recent clinical evidence was also reviewed, including the RELAY trial.

Rate this content's potential impact on patient outcomes

Thank you!

Please share some more information on the rating you have given